CapnoPharm will sponsor two pivotal clinical trials (CapnoDC^® and CapnoXal^®) to support regulatory approval, reimbursement, and access to the large global market of peritoneal and pleural cancer. These trials are key value-creation milestones and open multiple strategic exit opportunities within a five-year horizon.

We invite investors who share our vision to advance high-impact, ethically developed cancer therapies,  such as PIPAC and PITAC. The full investor pitch is available upon request.

Contact: m.reymond@capnopharm.com